Chronic Lymphocytic Leukemia | Specialty

Dr. Eradat on the Unmet Needs in CLL

September 19th 2019

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unmet needs in chronic lymphocytic leukemia.

Breakthrough Therapies Enrich Evolving CLL Paradigm

September 19th 2019

Herbert A. Eradat, MD, explains how insight into the pathogenesis of chronic lymphocytic leukemia is leading to novel treatment strategies and shed light on unmet needs in the field.

Secondary Cancer Risk Remains an Unresolved Issue in CLL

September 18th 2019

David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.

Novel Combos Are Shaking Up the CLL Landscape

September 15th 2019

The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications.

Future of PI3K Inhibition in FL and CLL

September 13th 2019

PI3K Inhibitors in Management of R/R Follicular Lymphoma

September 13th 2019

PI3K Inhibitors in Management of CLL

September 13th 2019

Common Toxicities With PI3K Inhibition

September 13th 2019

Role of PI3K Inhibitors in Treatment of B-cell Malignancies

September 13th 2019

Dr. Siddiqi on the Safety Profile of Liso-Cel in the TRANSCEND CLL 004 Trial

September 13th 2019

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the safety profile of lisocabtagene maraleucel (liso-cel; JCAR017) in the TRANSCEND CLL 004 trial.

Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL

September 12th 2019

Reducing or interrupting duvelisib treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival compared with ofatumumab while producing rapid and durable responses in heavily pretreated patients.

Curating Novel Combinations in CLL

September 11th 2019

Tanya Siddiqi, MD, discusses the novel agents that have emerged in the treatment paradigm for patients with chronic lymphocytic leukemia.

Dr. Ghia on ASCEND Trial Results for Previously Treated CLL

September 10th 2019

Paolo Ghia, MD, discusses the efficacy results of the ASCEND trial, which examined the use of acalabrutinib monotherapy in patients with previously treated chronic lymphocytic leukemia.

Dr. Eradat on Novel Therapy Vs Chemotherapy in CLL

September 7th 2019

Herbert A. Eradat, MD, compares novel therapies with cytotoxic chemotherapy in the treatment of patients with chronic lymphocytic leukemia.

Dr. Daver Compares Toxicity Profiles of TKIs in CML

August 29th 2019

Naval G. Daver, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses safety differences between the TKIs ponatinib, dasatinib (Sprycel) and nilotinib (Tasigna) in the treatment of patients with chronic myeloid leukemia.

Dr. Shadman on the Efficacy of Venetoclax in CLL

August 20th 2019

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the efficacy of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Acalabrutinib Shows Benefit in Ibrutinib-Treated Relapsed/Refractory CLL

August 19th 2019

Kerry A. Rogers, MD, highlights the findings of a study examining acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia and the next steps for the data.

FDA Grants Acalabrutinib Breakthrough Designation for CLL

August 14th 2019

The FDA has granted a breakthrough therapy designation to acalabrutinib (Calquence) for the treatment of patients with chronic lymphocytic leukemia.

Ibrutinib EU Indications Expanded in CLL and Waldenstrom Macroglobulinemia

August 14th 2019

The European Commission has expanded the approval of ibrutinib to include use in combination with obinutuzumab for adult patients with previously untreated chronic lymphocytic leukemia, and also in combination with rituximab for the treatment of adult patients with Waldenström macroglobulinemia.

Dr. Abedin on PI3K Inhibitors in CLL

August 12th 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the use of PI3K inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL).